CyberArk Software (CYBR) PT Raised to $57 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
CyberArk Software (CYBR) PT Raised to $63 at Imperial Capital
February 10, 2017 10:48 AM ESTImperial Capital raised its price target on CyberArk Software (NASDAQ: CYBR) to $63.00 (from $55.00) while maintaining a Outperform rating. CYBR reported 4Q16 revenue of $64.4mn and adjusted EPS of $0.41, above Street revenue estimates of 63.0mn and adjusted EPS estimates of $0.33.
Analyst Michael Kim... More
After-Hours Stock Movers 02/09: (INFN) (ATVI) (SWIR) Higher; (RSYS) (TCON) (YELP) Lower (more...)
February 9, 2017 6:31 PM ESTToday's After-Hours Movers
Radisys Corp (NASDAQ: RSYS) 15% LOWER; reported Q4 EPS of $0.04, in-line with the analyst estimate of $0.04. Revenue for the quarter came in at $40.6 million versus the consensus estimate of $42.06 million.
TRACON Pharmaceuticals (NASDAQ: TCON) 12.4% LOWER; reported top-line results from a randomized Phase 2 clinical trial of TRC105 in recurrent glioblastoma (GBM) funded and conducted by the Clinical Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). In the trial, TRC105 combined with Avastin® (bevacizumab) was... More
CyberArk Software (CYBR) Tops Q4 EPS by 8c
February 9, 2017 4:12 PM ESTCyberArk Software (NASDAQ: CYBR) reported Q4 EPS of $0.41, $0.08 better than the analyst estimate of $0.33. Revenue for the quarter came in at $64.4 million versus the consensus estimate of $63.01 million.
GUIDANCE:
CyberArk Software sees Q1 2017 EPS of $0.21-$0.23, versus the consensus of... More
